Safety profile evaluation of direct oral anticoagulants in surgical patients with polypharmacy: a retrospective analysis of clinical cases
https://doi.org/10.37489/2782-3784-myrwd-087
EDN: XYIOIW
Abstract
This article presents the results of a safety study of oral anticoagulants in surgical patients with polypharmacy. An analysis of medical records of inpatients receiving oral anticoagulants for the prevention of venous thromboembolic complications was conducted. Postoperative venous thromboembolism is one of the most common indications for the use of direct oral anticoagulants. Serious problems may arise during treatment and may be associated with age-related changes in the body, gender, and concomitant drug therapy.
About the Authors
E. R. Kadyseva
Kazan (Volga region) Federal University
Russian Federation
Russian Federation
Elvina R. Kadyseva — clinical pharmacologist, postgraduate student, senior lecturer, Department of Internal Medicine, Institute of Fundamental Medicine and Biology
Kazan
V. N. Khaziakhmetova
Kazan (Volga region) Federal University; Kazan State Medical Academy – Branch Campus of the FSBEI FPE RMACPE MOH
Russian Federation
Russian Federation
Veronika N. Khaziakhmetova — Cand. Sci. (Med.), clinical pharmacologist, Associate Professor of the Department of Internal Diseases at the Institute of Fundamental Medicine and Biology, Associate Professor of the Department of Clinical Pharmacology and Pharmacotherapy
Kazan
References
1. Greco A, Laudani C, Spagnolo M, et al. Pharmacology and Clinical Development of Factor XI Inhibitors. Circulation. 2023 Mar 14;147(11):897-913. doi: 10.1161/CIRCULATIONAHA.122.062353.
2. Приказ Минздрава России от 04.10.2022 N 646н "Об утверждении стандарта медицинской помощи взрослым при ожогах термических и химических, ожогах солнечных, ожогах дыхательных путей (диагностика и лечение)" (Зарегистрировано в Минюсте России 09.11.2022 N 70871). Режим доступа: https://rulaws.ru/acts/Prikaz-Minzdrava-Rossii-ot-04.10.2022-N-646n/.
3. Monégat M, Sermet C, Perronnin M, Rococo E. Polypharmacy: definitions, measurement and stakes involved review of the literature and measurement tests. Quest d’économie la Santé. 2014;204:1–8.
4. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012 Sep;65(9):989-95. doi: 10.1016/j.jclinepi.2012.02.018.
5. Foerster KI, Hermann S, Mikus G, Haefeli WE. Drug-Drug Interactions with Direct Oral Anticoagulants. Clin Pharmacokinet. 2020 Aug;59(8):967980. doi: 10.1007/s40262-020-00879-x. Erratum in: Clin Pharmacokinet. 2020 Dec;59(12):1647. doi: 10.1007/s40262-020-00954-3.
6. Payne RA, Avery AJ, Duerden M, et al. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. 2014 May; 70(5):575-81. doi: 10.1007/s00228-013-1639-9.
7. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015 Apr 7;13:74. doi: 10.1186/s12916-015-0322-7.
8. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012 Jan;11(1):83-94. doi: 10.1517/14740338.2012.631910.
9. Astrand B. Avoiding drug-drug interactions. Chemotherapy. 2009;55(4):215-20. doi: 10.1159/000218100.
10. Eggebrecht L, Nagler M, Göbel S, et al. Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists. J Am Geriatr Soc. 2019 Mar;67(3):463-470. doi: 10.1111/jgs.15712.
11. Sychev IN, Fedina LV, Gabrielyan DA, et al. Anticoagulant therapy with direct oral anticoagulants in the context of polypragmasy: a course to safety. Meditsinskiy sovet = Medical Council. 2022;(17):52-64. (In Russ.).
12. Sychev D.A. (ed.) Polypharmacy in clinical practice: problems and solutions/study guide. 2nd ed., corrected and supplemented. St. Petersburg: Center for Professional Education "Profession", 2018. 272 p., ill. ISBN 978-5-91884-106-8.
13. Fedina L.V., Sychev I.N., Rastvorova T.D., et al. Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis. Rational Pharmacotherapy in Cardiology. 2022;18(6):624-629. (In Russ.).
14. Mirzaev K.B., Ivashchenko D.V., Volodin I.V., et al. New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants. Rational Pharmacotherapy in Cardiology. 2020;16(5):670-677.
15. Burn Injury: A Study Guide. Edited by A.A. Kozka, O.S. Olifirov. – Blagoveshchensk, 2021, p. 85.
16. Cato L, Bailiff B, Price J, Ermogenous C, Hazeldine J, Lester W et al. Heparin resistance in severe thermal injury: a prospective cohort study. Burns & Trauma. 2021 Oct 20;9:tkab032. doi: 10.1093/burnst/tkab032.
17. Stanton EW, Manasyan A, Thompson CM, et al. Venous Thromboembolism Incidence, Risk Factors, and Prophylaxis in Burn Patients: A National Trauma Database Study. J Burn Care Res. 2025 Mar 4;46(2):393-399. doi: 10.1093/jbcr/irae171.
Review
For citations:
Kadyseva E.R., Khaziakhmetova V.N. Safety profile evaluation of direct oral anticoagulants in surgical patients with polypharmacy: a retrospective analysis of clinical cases. Real-World Data & Evidence. 2025;5(4):40-47. (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-087. EDN: XYIOIW
Views:
36
Email this article 
Post a Comment 